1. UK E-INFRASTRUCTURE, BARRIERS AND BENEFITS: AN INDUSTRY PERSPECTIVE Darren Green FRSC GlaxoSmithKline

2. Life sciences and the UK economy “The UK life science industry is one of the world leaders; it is the third largest contributor to economic growth in the UK with more than 4,000 companies, employing around 160,000 people and with a total annual turnover of over £50 billion. Its success is key to future economic growth and to our goal to rebalance the economy towards making new products and selling them to the world. Globally the industry is changing with more focus on collaboration, out-sourcing of research and earlier clinical trials with patients” David Cameron, 5 th December 2011

3. The R&D Productivity Gap Source: Burrill & Company; US Food and Drug Administration. Note: NMEs do not include BLAs

5. >40 internal engines 35 external engines Corporate Venture Fund GSK network c. 2010

6. Science  Diverse applications  Molecule Design  Disease & pathway modelling  Biomarker discovery  Trial Design  Patient Stratification  Pharmacovigilance etc  Requires a Diverse e-infrastructure

7. E-infrastructure ecosystem Janet

8. Potential Benefits  Application of e-science to life sciences challenges  faster R&D to better “products” Agrochemicals, drugs, diagnostics, treatment regimes  Facilitation of collaborations, knowledge transfer, innovation

9. Industry use of UK e-infrastructure “In the domain of high performance computing for life sciences, the Science and Technology Facilities council (STFC) runs an e-science project with a 10- year history. We are not aware of any life science company that makes of these resources”* * Response from the industry leads of the EU OpenPhacts IMI project to UK Research Council 2012

10. E-infrastructure barriers Janet CTAGCATG…. 

11. Summary  UK e-infrastructure underutilised by Life Sciences industry  Investments in hardware need balancing by investments in people, skills & software  Realise the potential of the UK in E-health  Train the next generation of scientists  the “data scientist”  Facilitate collaborations between industry and academia  Proof of concept studies  Data sharing

12. Acknowledgements Douglas KellBBSRC Ian DixAstraZeneca Robert GlenUniversity of Cambridge Peter CoveneyUniversity College London Anne-Marie CoriatMRC Lesley ThompsonEPSRC ELC Life sciences members Contributors to the ELC Life Sciences report Sophia AnaniadouUniversity of Manchester Andy BrassUniversity of Manchester Klaus BengstAstra Zeneca David BurtRoslin Institute Andy EllisBiocats Jonathan EssexUniversity of Southampton Wendy FilsellUnilever Paul FinnInhibox Chris FoleyGlaxoSmithKline Mark ForsterSyngenta Keith GodfreyUniversity of Southampton Lee HarlandIndependent Consultant Vincent HughesFujitsu UK Janette JonesUnilever Amanda LaneUnilever Chris LarminieGlaxoSmithKline Louise LeongABPI Nick LynchAstra Zeneca Ian MitchellFujitsu UK Chris MolloyIDBS Paul MortensenAstex Pharmaceuticals Christine OrengoUniversity College London Chris Page GlaxoSmithKline Anthony RoweJohnson & Johnson Philippe SanseauGlaxoSmithKline Willie Taylor NIMR Janet ThorntonEMBL-EBI Jon WrennallFujitsu UK